News | Stents Bioresorbable | October 16, 2015

Amaranth Medical Completes Two Studies, Initiates Third for its and Sirolimus-Eluting Bioresorbable Scaffold

Fortitude bioresorbable stent clinical findings presented at TCT 2015

Amaranth Medical Bioresorbable Scaffold, Fortitude stent

October 16, 2015 — Enrollment has successfully concluded in its multi-center, international CE mark clinical trials MEND-II and RENASCENT-I for the assessment of the Amaranth Medical Fortitude sirolimus-eluting bioresorbable scaffold (BRS) in patients with symptomatic coronary artery disease. 

All patients have entered the nine-month follow-up period, which is expected to conclude by mid-2016. Juan F. Granada, M.D., chief scientific advisor of Amaranth and executive director and chief innovation officer of the CRF-Skirball Center for Innovation, presented findings from these studies on at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting this week. 

"Preliminary findings of these important studies are very exciting and continue to highlight the competitive advantages of the technology. Fortitude demonstrated a high device success rate and excellent peri-procedural clinical outcomes in all patients enrolled," Granada said. "Our experience with this 150 micron scaffold has been quite positive, but without any doubt the future relies on the miniaturization of current BRS technologies, leading to easier navigation and a reduction of current thrombotic risk."

In addition, Amaranth announced plans to initiate RENASCENT-II, a study of a new 120 micron BRS. The study will take place in several centers in Italy and Colombia, South America with Antonio Colombo, M.D., director of the hemodynamics division at Ospedale San Raffaele in Milan, Italy, and Granada serving as co-primary investigators.

"We plan to apply for a CE mark following the conclusion of the nine-month patient follow-up period," added Kamal Ramzipoor, president and CEO of Amaranth. "If granted a CE mark, we would be in a position to commercialize our first product in 2017."

Colombo, primary investigator of the RENASCENT-I trial and co-primary investigator of RENASCENT-II, added, "The excellent results of RENASCENT-I are paving the way for RENASCENT-II, a study with a new 120 micron BRS. We are entering the era of BRS without compromises."

In addition to the 150- and 120-micron scaffolds, Amaranth's product pipeline includes the development of scaffolds under 100 micron wall thickness, which have demonstrated the ability to maintain biomechanical properties similar to previous generations of BRS. It is Amaranth's proprietary polymer's mechanical properties that enable the construction of scaffolds with strut thicknesses similar to those of metallic drug-eluting stents, without compromising on the key attributes such as radial strength, surface area and recoil.

"We believe that Amaranth is in a unique position to continue the miniaturization process of their devices while retaining the optimal biomechanical properties demonstrated in their earlier generation devices, including enhanced deliverability and treatment of more complex atherosclerotic lesions, thus becoming a trend setter in the bioresorbable scaffold field," Granada concluded.

For more information: www.amaranthmedical.com


Related Content

News | Stents Bioresorbable

May 30, 2024 — Biotronik announced the presentation of the 12-month results from the BIONETIC-I study this week at LINC ...

Home May 30, 2024
Home
News | Stents Bioresorbable

February 14, 2024 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, today announced that ...

Home February 14, 2024
Home
News | Stents Bioresorbable

October 30, 2023 — Abbott announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit BTK ...

Home October 30, 2023
Home
News | Stents Bioresorbable

September 5, 2023 — New data from the BIOMAG-I first-in-human trial shed light on the vascular healing process following ...

Home September 05, 2023
Home
News | Stents Bioresorbable

March 16, 2023 — Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator, presented the latest results of the ...

Home March 16, 2023
Home
News | Stents Bioresorbable

October 11, 2022 — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced that it has ...

Home October 11, 2022
Home
News | Stents Bioresorbable

September 28, 2022 — In the "TCT Innovation" session Prof. Michael Haude, BIOMAG-I Coordinating Clinical Investigator ...

Home September 28, 2022
Home
News | Stents Bioresorbable

September 27, 2022 — BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster ...

Home September 27, 2022
Home
News | Stents Bioresorbable

December 16, 2020 — Efemoral Medical announced the first-in-human (FIH) use of the its Efemoral bioresorbable vascular ...

Home December 16, 2020
Home
Feature | Stents Bioresorbable

September 3, 2020 — Abbott today announced the start of the LIFE-BTK clinical trial to evaluate the safety and ...

Home September 03, 2020
Home
Subscribe Now